{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:46:02Z","timestamp":1790718362466,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aggregation of intracellular tau protein is a major hallmark of Alzheimer\u2019s disease (AD). The extent and the stereotypical spread of tau pathology in the AD brain are correlated with cognitive decline during disease progression. Here we present an in-depth analysis of endogenous tau fragmentation in a well-characterized cohort of AD and age-matched control subjects. Using protein mass spectrometry and Edman degradation to interrogate endogenous tau fragments in the human brain, we identified two novel proteolytic sites, G323 and G326, as major tau cleavage events in both normal and AD cortex. These sites are located within the sequence recently identified as the structural core of tau protofilaments, suggesting an inhibitory mechanism of fibril formation. In contrast, a different set of novel cleavages showed a distinct increase in late stage AD. These disease-associated sites are located outside of the protofilament core sequence. We demonstrate that calpain 1 specifically cleaves at both the normal and diseased sites <jats:italic>in vitro<\/jats:italic>, and the site selection is conformation-dependent. Monomeric tau is predominantly cleaved at G323\/G326 (normal sites), whereas oligomerization increases cleavages at the late-AD-associated sites. The fragmentation patterns specific to disease and healthy states suggest novel regulatory mechanisms of tau aggregation in the human brain.<\/jats:p>","DOI":"10.1038\/s41598-018-35130-y","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T11:46:23Z","timestamp":1541591183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Calpain-mediated tau fragmentation is altered in Alzheimer\u2019s disease progression"],"prefix":"10.1038","volume":"8","author":[{"given":"Hsu-Hsin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Auger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5875-9026","authenticated-orcid":false,"given":"Oskar","family":"Adolfsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorianne","family":"Rey-Bellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Lafrance-Vanasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5864-5253","authenticated-orcid":false,"given":"Brad A.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pihlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Muhs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gai","family":"Ayalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin R.","family":"Wildsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel P.","family":"van der Brug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"35130_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0197-4580(99)00063-9","volume":"20","author":"E Grober","year":"1999","unstructured":"Grober, E. et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging 20, 573\u2013579 (1999).","journal-title":"Neurobiol Aging"},{"key":"35130_CR2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/brain\/aww334","volume":"140","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo, M. J. et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748\u2013763, https:\/\/doi.org\/10.1093\/brain\/aww334 (2017).","journal-title":"Brain"},{"key":"35130_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3233\/JAD-160316","volume":"55","author":"J Dronse","year":"2017","unstructured":"Dronse, J. et al. In vivo Patterns of Tau Pathology, Amyloid-beta Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer\u2019s Disease. J Alzheimers Dis 55, 465\u2013471, https:\/\/doi.org\/10.3233\/JAD-160316 (2017).","journal-title":"J Alzheimers Dis"},{"key":"35130_CR4","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin, A. et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease. Brain 140, 3286\u20133300, https:\/\/doi.org\/10.1093\/brain\/awx243 (2017).","journal-title":"Brain"},{"key":"35130_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bpa.12486","volume":"27","author":"DMA Mann","year":"2017","unstructured":"Mann, D. M. A. & Snowden, J. S. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. Brain Pathol 27, 723\u2013736, https:\/\/doi.org\/10.1111\/bpa.12486 (2017).","journal-title":"Brain Pathol"},{"key":"35130_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-pathol-012615-044116","volume":"11","author":"J Hay","year":"2016","unstructured":"Hay, J., Johnson, V. E., Smith, D. H. & Stewart, W. Chronic Traumatic Encephalopathy: The Neuropathological Legacy of Traumatic Brain Injury. Annu Rev Pathol 11, 21\u201345, https:\/\/doi.org\/10.1146\/annurev-pathol-012615-044116 (2016).","journal-title":"Annu Rev Pathol"},{"key":"35130_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrneurol.2015.225","volume":"12","author":"K Iqbal","year":"2016","unstructured":"Iqbal, K., Liu, F. & Gong, C. X. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol 12, 15\u201327, https:\/\/doi.org\/10.1038\/nrneurol.2015.225 (2016).","journal-title":"Nat Rev Neurol"},{"key":"35130_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0896-6273(92)90117-V","volume":"8","author":"M Goedert","year":"1992","unstructured":"Goedert, M., Spillantini, M. G., Cairns, N. J. & Crowther, R. A. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8, 159\u2013168 (1992).","journal-title":"Neuron"},{"key":"35130_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.tins.2014.08.004","volume":"37","author":"H Zempel","year":"2014","unstructured":"Zempel, H. & Mandelkow, E. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci 37, 721\u2013732, https:\/\/doi.org\/10.1016\/j.tins.2014.08.004 (2014).","journal-title":"Trends Neurosci"},{"key":"35130_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.bbadis.2009.09.008","volume":"1802","author":"J Gotz","year":"2010","unstructured":"Gotz, J. et al. Animal models reveal role for tau phosphorylation in human disease. Biochim Biophys Acta 1802, 860\u2013871, https:\/\/doi.org\/10.1016\/j.bbadis.2009.09.008 (2010).","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"35130_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"Heiko Braak","year":"1995","unstructured":"Braak, H. & Braak, E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol Aging 16, 271\u2013278; discussion 278\u2013284 (1995).","journal-title":"Neurobiology of Aging"},{"key":"35130_CR12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70, 960\u2013969, https:\/\/doi.org\/10.1097\/NEN.0b013e318232a379 (2011).","journal-title":"J Neuropathol Exp Neurol"},{"key":"35130_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neurobiolaging.2017.10.002","volume":"62","author":"S Tsartsalis","year":"2017","unstructured":"Tsartsalis, S., Xekardaki, A., Hof, P. R., Kovari, E. & Bouras, C. Early Alzheimer-type lesions in cognitively normal subjects. Neurobiol Aging 62, 34\u201344, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.10.002 (2017).","journal-title":"Neurobiol Aging"},{"key":"35130_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1385-299X(00)00018-0","volume":"5","author":"C Janke","year":"2000","unstructured":"Janke, C., Beck, M., Holzer, M., Bigl, V. & Arendt, T. Analysis of the molecular heterogeneity of the microtubule-associated protein tau by two-dimensional electrophoresis and RT-PCR. Brain Res Brain Res Protoc 5, 231\u2013242 (2000).","journal-title":"Brain Res Brain Res Protoc"},{"key":"35130_CR15","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/nm.4199","volume":"22","author":"X Zhao","year":"2016","unstructured":"Zhao, X. et al. Caspase-2 cleavage of tau reversibly impairs memory. Nat Med 22, 1268\u20131276, https:\/\/doi.org\/10.1038\/nm.4199 (2016).","journal-title":"Nat Med"},{"key":"35130_CR16","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1093\/hmg\/ddv351","volume":"24","author":"SE Matsumoto","year":"2015","unstructured":"Matsumoto, S. E. et al. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties. Hum Mol Genet 24, 6403\u20136416, https:\/\/doi.org\/10.1093\/hmg\/ddv351 (2015).","journal-title":"Hum Mol Genet"},{"key":"35130_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fnagi.2018.00027","volume":"10","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y. et al. Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer\u2019s Disease. Front Aging Neurosci 10, 27, https:\/\/doi.org\/10.3389\/fnagi.2018.00027 (2018).","journal-title":"Front Aging Neurosci"},{"key":"35130_CR18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/NEN.0b013e31817275c7","volume":"67","author":"G Basurto-Islas","year":"2008","unstructured":"Basurto-Islas, G. et al. Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J Neuropathol Exp Neurol 67, 470\u2013483, https:\/\/doi.org\/10.1097\/NEN.0b013e31817275c7 (2008).","journal-title":"J Neuropathol Exp Neurol"},{"key":"35130_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.neurobiolaging.2004.09.019","volume":"26","author":"AL Guillozet-Bongaarts","year":"2005","unstructured":"Guillozet-Bongaarts, A. L. et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer\u2019s disease. Neurobiol Aging 26, 1015\u20131022, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2004.09.019 (2005).","journal-title":"Neurobiol Aging"},{"key":"35130_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1046\/j.1471-4159.2000.0750624.x","volume":"75","author":"L Fasulo","year":"2000","unstructured":"Fasulo, L. et al. The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J Neurochem 75, 624\u2013633 (2000).","journal-title":"J Neurochem"},{"key":"35130_CR21","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.1523\/JNEUROSCI.1988-04.2004","volume":"24","author":"PM Horowitz","year":"2004","unstructured":"Horowitz, P. M. et al. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer\u2019s disease. J Neurosci 24, 7895\u20137902, https:\/\/doi.org\/10.1523\/JNEUROSCI.1988-04.2004 (2004).","journal-title":"J Neurosci"},{"key":"35130_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1172\/JCI20640","volume":"114","author":"RA Rissman","year":"2004","unstructured":"Rissman, R. A. et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114, 121\u2013130, https:\/\/doi.org\/10.1172\/JCI20640 (2004).","journal-title":"J Clin Invest"},{"key":"35130_CR23","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm.3700","volume":"20","author":"Z Zhang","year":"2014","unstructured":"Zhang, Z. et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer\u2019s disease. Nat Med 20, 1254\u20131262, https:\/\/doi.org\/10.1038\/nm.3700 (2014).","journal-title":"Nat Med"},{"key":"35130_CR24","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1073\/pnas.90.7.2628","volume":"90","author":"K Saito","year":"1993","unstructured":"Saito, K., Elce, J. S., Hamos, J. E. & Nixon, R. A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 90, 2628\u20132632 (1993).","journal-title":"Proc Natl Acad Sci USA"},{"key":"35130_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1749-6632.1994.tb44402.x","volume":"747","author":"RA Nixon","year":"1994","unstructured":"Nixon, R. A. et al. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer\u2019s disease. Ann N Y Acad Sci 747, 77\u201391 (1994).","journal-title":"Ann N Y Acad Sci"},{"key":"35130_CR26","doi-asserted-by":"publisher","first-page":"37755","DOI":"10.1074\/jbc.M507475200","volume":"280","author":"F Liu","year":"2005","unstructured":"Liu, F. et al. Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem 280, 37755\u201337762, https:\/\/doi.org\/10.1074\/jbc.M507475200 (2005).","journal-title":"J Biol Chem"},{"key":"35130_CR27","doi-asserted-by":"publisher","first-page":"7061","DOI":"10.1523\/JNEUROSCI.18-18-07061.1998","volume":"18","author":"N Canu","year":"1998","unstructured":"Canu, N. et al. Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J Neurosci 18, 7061\u20137074 (1998).","journal-title":"J Neurosci"},{"key":"35130_CR28","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1523\/JNEUROSCI.1125-05.2005","volume":"25","author":"SY Park","year":"2005","unstructured":"Park, S. Y. & Ferreira, A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci 25, 5365\u20135375, https:\/\/doi.org\/10.1523\/JNEUROSCI.1125-05.2005 (2005).","journal-title":"J Neurosci"},{"key":"35130_CR29","doi-asserted-by":"publisher","first-page":"20931","DOI":"10.1074\/jbc.M111.316232","volume":"287","author":"A Tennstaedt","year":"2012","unstructured":"Tennstaedt, A. et al. Human high temperature requirement serine protease A1 (HTRA1) degrades tau protein aggregates. J Biol Chem 287, 20931\u201320941, https:\/\/doi.org\/10.1074\/jbc.M111.316232 (2012).","journal-title":"J Biol Chem"},{"key":"35130_CR30","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1046\/j.1471-4159.1996.67051846.x","volume":"67","author":"E Bednarski","year":"1996","unstructured":"Bednarski, E. & Lynch, G. Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsins B and L. J Neurochem 67, 1846\u20131855 (1996).","journal-title":"J Neurochem"},{"key":"35130_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","volume":"142","author":"LM Ittner","year":"2010","unstructured":"Ittner, L. M. et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer\u2019s disease mouse models. Cell 142, 387\u2013397, https:\/\/doi.org\/10.1016\/j.cell.2010.06.036 (2010).","journal-title":"Cell"},{"key":"35130_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15295","volume":"8","author":"L Zhou","year":"2017","unstructured":"Zhou, L. et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat Commun 8, 15295, https:\/\/doi.org\/10.1038\/ncomms15295 (2017).","journal-title":"Nat Commun"},{"key":"35130_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-neuro-072116-031153","volume":"40","author":"M Goedert","year":"2017","unstructured":"Goedert, M., Eisenberg, D. S. & Crowther, R. A. Propagation of Tau Aggregates and Neurodegeneration. Annu Rev Neurosci 40, 189\u2013210, https:\/\/doi.org\/10.1146\/annurev-neuro-072116-031153 (2017).","journal-title":"Annu Rev Neurosci"},{"key":"35130_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1474-4422(17)30037-6","volume":"16","author":"BE Stopschinski","year":"2017","unstructured":"Stopschinski, B. E. & Diamond, M. I. The prion model for progression and diversity of neurodegenerative diseases. Lancet Neurol 16, 323\u2013332, https:\/\/doi.org\/10.1016\/S1474-4422(17)30037-6 (2017).","journal-title":"Lancet Neurol"},{"key":"35130_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.neuron.2016.09.055","volume":"92","author":"SK Kaufman","year":"2016","unstructured":"Kaufman, S. K. et al. Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron 92, 796\u2013812, https:\/\/doi.org\/10.1016\/j.neuron.2016.09.055 (2016).","journal-title":"Neuron"},{"key":"35130_CR36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.neuron.2014.04.047","volume":"82","author":"DW Sanders","year":"2014","unstructured":"Sanders, D. W. et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271\u20131288, https:\/\/doi.org\/10.1016\/j.neuron.2014.04.047 (2014).","journal-title":"Neuron"},{"key":"35130_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.nbd.2017.06.005","volume":"106","author":"P Reilly","year":"2017","unstructured":"Reilly, P. et al. Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation. Neurobiol Dis 106, 222\u2013234, https:\/\/doi.org\/10.1016\/j.nbd.2017.06.005 (2017).","journal-title":"Neurobiol Dis"},{"key":"35130_CR38","doi-asserted-by":"publisher","first-page":"11406","DOI":"10.1523\/JNEUROSCI.1230-17.2017","volume":"37","author":"S Narasimhan","year":"2017","unstructured":"Narasimhan, S. et al. Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain. J Neurosci 37, 11406\u201311423, https:\/\/doi.org\/10.1523\/JNEUROSCI.1230-17.2017 (2017).","journal-title":"J Neurosci"},{"key":"35130_CR39","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","volume":"16","author":"SH Lee","year":"2016","unstructured":"Lee, S. H. et al. Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement. Cell Rep 16, 1690\u20131700, https:\/\/doi.org\/10.1016\/j.celrep.2016.06.099 (2016).","journal-title":"Cell Rep"},{"key":"35130_CR40","doi-asserted-by":"publisher","first-page":"14893","DOI":"10.1074\/jbc.M115.652693","volume":"290","author":"H Mirbaha","year":"2015","unstructured":"Mirbaha, H., Holmes, B. B., Sanders, D. W., Bieschke, J. & Diamond, M. I. Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation. J Biol Chem 290, 14893\u201314903, https:\/\/doi.org\/10.1074\/jbc.M115.652693 (2015).","journal-title":"J Biol Chem"},{"key":"35130_CR41","doi-asserted-by":"publisher","first-page":"e76523","DOI":"10.1371\/journal.pone.0076523","volume":"8","author":"JE Meredith Jr.","year":"2013","unstructured":"Meredith, J. E. Jr. et al. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer\u2019s disease. PLoS One 8, e76523, https:\/\/doi.org\/10.1371\/journal.pone.0076523 (2013).","journal-title":"PLoS One"},{"key":"35130_CR42","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato, C. et al. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 97, 1284\u20131298 e1287, https:\/\/doi.org\/10.1016\/j.neuron.2018.02.015 (2018).","journal-title":"Neuron"},{"key":"35130_CR43","doi-asserted-by":"publisher","first-page":"D351","DOI":"10.1093\/nar\/gkv1201","volume":"44","author":"JG Perez-Silva","year":"2016","unstructured":"Perez-Silva, J. G., Espanol, Y., Velasco, G. & Quesada, V. The Degradome database: expanding roles of mammalian proteases in life and disease. Nucleic Acids Res 44, D351\u2013355, https:\/\/doi.org\/10.1093\/nar\/gkv1201 (2016).","journal-title":"Nucleic Acids Res"},{"key":"35130_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1432-1033.1995.009_1.x","volume":"233","author":"LS Yang","year":"1995","unstructured":"Yang, L. S. & Ksiezak-Reding, H. Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments. Eur J Biochem 233, 9\u201317 (1995).","journal-title":"Eur J Biochem"},{"issue":"2","key":"35130_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.0.CO;2-6","volume":"53","author":"Han-qing Xie","year":"1998","unstructured":"Xie, H. Q. & Johnson, G. V. Calcineurin inhibition prevents calpain-mediated proteolysis of tau in differentiated PC12 cells. J Neurosci Res 53, 153\u2013164, 10.1002\/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.0.CO;2-6 (1998).","journal-title":"Journal of Neuroscience Research"},{"key":"35130_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.lfs.2005.04.058","volume":"78","author":"MW Warren","year":"2005","unstructured":"Warren, M. W. et al. Concurrent calpain and caspase-3 mediated proteolysis of alpha II-spectrin and tau in rat brain after methamphetamine exposure: a similar profile to traumatic brain injury. Life Sci 78, 301\u2013309, https:\/\/doi.org\/10.1016\/j.lfs.2005.04.058 (2005).","journal-title":"Life Sci"},{"key":"35130_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JAD-2009-0908","volume":"16","author":"JY Zhang","year":"2009","unstructured":"Zhang, J. Y. et al. Inhibition of autophagy causes tau proteolysis by activating calpain in rat brain. J Alzheimers Dis 16, 39\u201347, https:\/\/doi.org\/10.3233\/JAD-2009-0908 (2009).","journal-title":"J Alzheimers Dis"},{"key":"35130_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2010.09.008","volume":"32","author":"S Garg","year":"2011","unstructured":"Garg, S., Timm, T., Mandelkow, E. M., Mandelkow, E. & Wang, Y. Cleavage of Tau by calpain in Alzheimer\u2019s disease: the quest for the toxic 17 kD fragment. Neurobiol Aging 32, 1\u201314, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.09.008 (2011).","journal-title":"Neurobiol Aging"},{"key":"35130_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547, 185\u2013190, https:\/\/doi.org\/10.1038\/nature23002 (2017).","journal-title":"Nature"},{"key":"35130_CR50","doi-asserted-by":"publisher","first-page":"13982","DOI":"10.1021\/ja305470p","volume":"134","author":"V Daebel","year":"2012","unstructured":"Daebel, V. et al. beta-Sheet core of tau paired helical filaments revealed by solid-state NMR. J Am Chem Soc 134, 13982\u201313989, https:\/\/doi.org\/10.1021\/ja305470p (2012).","journal-title":"J Am Chem Soc"},{"key":"35130_CR51","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1073\/pnas.97.10.5129","volume":"97","author":"M von Bergen","year":"2000","unstructured":"von Bergen, M. et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci USA 97, 5129\u20135134 (2000).","journal-title":"Proc Natl Acad Sci USA"},{"key":"35130_CR52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0014-5793(99)01427-1","volume":"461","author":"S Yen","year":"1999","unstructured":"Yen, S., Easson, C., Nacharaju, P., Hutton, M. & Yen, S. H. FTDP-17 tau mutations decrease the susceptibility of tau to calpain I digestion. FEBS Lett 461, 91\u201395 (1999).","journal-title":"FEBS Lett"},{"key":"35130_CR53","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/0006-291X(89)91150-9","volume":"163","author":"GV Johnson","year":"1989","unstructured":"Johnson, G. V., Jope, R. S. & Binder, L. I. Proteolysis of tau by calpain. Biochem Biophys Res Commun 163, 1505\u20131511 (1989).","journal-title":"Biochem Biophys Res Commun"},{"key":"35130_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/35012636","volume":"405","author":"MS Lee","year":"2000","unstructured":"Lee, M. S. et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360\u2013364, https:\/\/doi.org\/10.1038\/35012636 (2000).","journal-title":"Nature"},{"key":"35130_CR55","doi-asserted-by":"publisher","first-page":"E4887","DOI":"10.1073\/pnas.1402627111","volume":"111","author":"HM Chow","year":"2014","unstructured":"Chow, H. M. et al. CDK5 activator protein p25 preferentially binds and activates GSK3beta. Proc Natl Acad Sci USA 111, E4887\u20134895, https:\/\/doi.org\/10.1073\/pnas.1402627111 (2014).","journal-title":"Proc Natl Acad Sci USA"},{"key":"35130_CR56","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/nrd.2016.212","volume":"15","author":"Y Ono","year":"2016","unstructured":"Ono, Y., Saido, T. C. & Sorimachi, H. Calpain research for drug discovery: challenges and potential. Nat Rev Drug Discov 15, 854\u2013876, https:\/\/doi.org\/10.1038\/nrd.2016.212 (2016).","journal-title":"Nat Rev Drug Discov"},{"key":"35130_CR57","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 15, 673\u2013684, https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3 (2016).","journal-title":"Lancet Neurol"},{"key":"35130_CR58","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1021\/acs.jproteome.5b01001","volume":"15","author":"NR Barthelemy","year":"2016","unstructured":"Barthelemy, N. R. et al. Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. J Proteome Res 15, 667\u2013676, https:\/\/doi.org\/10.1021\/acs.jproteome.5b01001 (2016).","journal-title":"J Proteome Res"},{"key":"35130_CR59","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/neup.12189","volume":"35","author":"TG Beach","year":"2015","unstructured":"Beach, T. G. et al. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology 35, 354\u2013389, https:\/\/doi.org\/10.1111\/neup.12189 (2015).","journal-title":"Neuropathology"},{"key":"35130_CR60","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol"},{"key":"35130_CR61","doi-asserted-by":"publisher","first-page":"e72301","DOI":"10.1371\/journal.pone.0072301","volume":"8","author":"C Theunis","year":"2013","unstructured":"Theunis, C. et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One 8, e72301, https:\/\/doi.org\/10.1371\/journal.pone.0072301 (2013).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35130-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35130-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35130-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:22:01Z","timestamp":1671621721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35130-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["35130"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-35130-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"13 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.H.C., S.H.L., P.L., P.A., J.L.V., B.F., J.E. and K.R.W. are salaried employees of Genentech. O.A., L.R.B., M.P., A.M. and A.P. are salaried employees of A.C. Immune S.A. T.G.B.\u2019s work is funded by institutes and foundations listed above in acknowledgements. M.P.vd.B. is the co-founder of Vivid Genomics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16725"}}